Vaccine Adjuvants Market size is poised to surpass USD 4 billion by the end of 2035, growing at a CAGR of 4.70% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of vaccine adjuvants was over USD 2 billion. The growth of the vaccine adjuvants market can be attributed to the growing prevalence of infectious and allergy diseases such as HIV/AIDS, tuberculosis (TB), malaria, and neglected infectious diseases along with increasing demand for advanced and improved vaccines. NTDs encompass a diverse group of infections caused by parasites, bacteria, fungi, viruses, and other non-communicable pathogens. In addition, there were 1.6 million deaths from TB in 2021 (including 187 000 HIV-positive individuals). According to the World Health Organization, TB is the 13th leading cause of death and the second leading infectious killer in the world after COVID-19. Vaccine adjuvants are substances that improve the effectiveness of vaccines. The growing prevalence of infectious diseases has caused an increase in demand for more effective vaccines, which has in turn contributed to greater research and development of new vaccine adjuvants.
In addition to these, factors that are believed to fuel the vaccine adjuvants market growth of vaccine adjuvants include an increase in financial support from governments and private organizations for the development of vaccines and the growing demand for safe and effective immunization are expected to have a positive impact on the growth of the global vaccine adjuvants market. In addition, funding for vaccine research and infectious disease research is expected to enhance the lucrative prospects for vaccine adjuvants. For instance, to prevent epidemics, detect disease threats, and respond rapidly and effectively to epidemics, the US government announced a funding of USD 122 million for Indian medical research institutes in June 2022.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
4.70% |
|
Base Year Market Size (2022) |
USD 2 Billion |
|
Forecast Year Market Size (2035) |
USD 4 Billion |
|
Regional Scope |
|
Product Type (Adjuvant Emulsions, Pathogen Components, Saponin-based Adjuvants, Particulate Adjuvants)
The global vaccine adjuvants market is segmented and analyzed for demand and supply by product type into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants and others. Out of these, the adjuvant emulsions segment is estimated to gain the largest vaccine adjuvants market share of about ~29% in the year 2035. The increasing demand for adjuvant emulsions in the vaccine market owing to their capability to enhance the efficacy of the vaccine, as well as the rising awareness about the importance of immunization among the population are major factors driving the growth of this segment. For instance, a number of emulsion adjuvants have been used in commercially available influenza vaccines, such as MF59 and AS03, and their composition and performance have been extensively studied and reported. Moreover, increasing government initiatives to promote the use of adjuvant-containing vaccines to reduce the cost of the vaccine delivery system and enhance the overall efficiency of the vaccine are also contributing to the growth of this segment.
Route of Administration (Intramuscular, Subcutaneous, Oral Route)
The global vaccine adjuvants market is segmented and analyzed for demand and supply by route of administration into intramuscular, subcutaneous, oral route and others. Out of these, the intramuscular segment is estimated to gain the significant vaccine adjuvants market share of about ~37% in the year 2035. The intramuscular route of administration is becoming increasingly popular among the patient population owing to its ability to provide a more sustained release of the vaccine, thereby improving the efficiency of the vaccine. Research has shown that 30 to 50% of intended intramuscular injections succeed, with the remainder resulting in inadvertent subcutaneous drug placement. Additionally, intramuscular injections are considered to be less painful than other routes of administration, making them more desirable for patients. These factors are anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global vaccine adjuvants market includes the following segments:
|
By Product Type |
|
|
By Route of Administration |
|
|
By Disease Type |
|
|
By Application |
|
|
By Application Category |
|
North American Market Forecast
The market share of vaccine adjuvants in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~35% by the end of 2035. The growth of the vaccine adjuvants market can be attributed majorly to the large population of elderly individuals and the increasing prevalence of chronic diseases, such as cancer, diabetes, and heart disease. Vaccine adjuvants enhance the immune system's response to the vaccine, resulting in a stronger and more effective response. With high recommendations for children’s vaccines, the demand for vaccine adjuvants in North America is expected to increase. For instance, United States standard recommendations include 10 vaccines for children between the ages of birth and 10 including hepatitis A (HepA); hepatitis B (HepB); RV; diphtheria, tetanus, and others. Additionally, increasing awareness about the importance of vaccinations, advances in vaccine technologies such as mRNA, and the growing adoption of preventive healthcare measures are likely to drive the growth of the market in this region. mRNA vaccines have revolutionized the speed of development and deployment of vaccines. mRNA vaccines are based on messenger RNA which provides instructions to cells to produce proteins that stimulate an immune response. These factors are anticipated to boost the vaccine adjuvants market growth during the forecast period.
APAC Market Statistics
The Asia Pacific vaccine adjuvants market is estimated to be the second largest, registering a share of about ~24% by the end of 2035. The growth of the market can be attributed majorly to the increased investment in vaccine research and development as well as the growing demand for combined vaccines. It was observed that a total of over USD 1 billion has been invested in Chinese vaccine research and development. A further 11.35 million doses of Covishield were exported by India in the year 2021. These doses were sent to 92 countries, including health workers and peacekeepers from the UN. Additionally, the rising prevalence of lifestyle-related diseases such as cancer and diabetes, as well as high prevalence of infectious diseases such as malaria and dengue, are expected to drive the demand for vaccines in the region, thus driving the growth of the vaccine adjuvant market in the Asia Pacific region.
Europe Market Forecast
Further, the vaccine adjuvants market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the presence of a large number of vaccine manufacturers in the region and the increasing government support for vaccination programs. Additionally, Europe is also witnessing an increase in the prevalence of chronic diseases resulting in an increase in vaccine demand. Vaccines work by introducing a weakened or inactive form of a virus or bacteria into the body, prompting the immune system to produce antibodies and build immunity. Adjuvants are added to vaccines to enhance the body’s immune response and to reduce the amount of the active ingredient, or antigen, needed in a vaccine. This makes them more effective at combating chronic diseases and are anticipated to boost the vaccine adjuvants market growth during the forecast period.
As the basis for their applications for regulatory approval, Sanofi and GSK plc intend to submit data from their booster and Phase 3 efficacy trials. The data they plan to submit is expected to include the full results of their Phase 3 efficacy trial of the vaccine, as well as data from their booster trial, which is designed to assess the efficacy of the vaccine after a booster dose.
GSK plc and SK Bioscience have submitted an application for a biologics license to the Korean Ministry of Food and Drug Safety for their SKYCovione after receiving positive Phase III clinical results. It is a candidate COVID-19 vaccine based on recombinant protein that has been adjuvant with GSK's pandemic adjuvant.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?